AI Case Study
Researchers at University of Lisbon accelerate drug discovery with the use of machine learning
Researchers at University of Lisbon, University of Cambridge, Friedrich-Schiller-University Jena, Federal University of Minas Gerais and Universidad de la Rioja are using machine learning to study how drug candidates and their targets interact to treat diseases. The algorithm that the team developed was able to identify that β-lapachone binds strongly to 5-lipoxygenase, an enzyme associated with human tumours.
Pharmaceuticals And Biotech
"Now, a multidisciplinary team of researchers believes artificial intelligence could help out in pharmacology studies. The team’s new approach successfully identified a potent inhibitor for 5-lipoxygenase, an enzyme that is over-expressed in a range of human tumours.
Co-author Tiago Rodrigues, at the University of Lisbon, Portugal, says that machine learning can go way beyond more classical molecular docking. ‘[Our] tool does not depend on the structure of proteins, so it can be applied in cases where molecular docking might not,’ he says. This new artificial intelligence tool is also quicker, hence cheaper. ‘Docking tends to be computationally expensive, whereas we can profile one molecule against thousands of drug targets in less than 10 minutes,’ he adds.
"Researchers used two different machine learning methods: ‘One gives a bind/don’t bind answer … and the other uses several decision trees to predict an affinity value,’ explains Bernardes. Then, the algorithm gives a prediction. In this case, it suggested likely targets for the natural product β-lapachone – among them enzyme 5-lipoxygenase.
The team’s chemists also synthesised a set of eight β-lapachone analogues, and tested their binding affinity to 5-lipoxygenase. None of them outperformed β-lapachone anticancer activity, however. The algorithm had found a perfect match. This highlights the importance of the structure and substitution pattern for bioactivity. To further analyse how β-lapachone binds to its target enzyme, Bernardes and co-workers created enzyme models and carried out computational studies that confirmed what they had found in the lab – β-lapachone binds strongly to the enzyme’s active site."
R And D
Core Research And Development
"Computers and chemists have been friendly for a long time. But when it comes to drug discovery, current computational methods are often too drawn out and inefficient to identify the mechanism of action of drugs.
Identifying how drug candidates interact with their target to treat disease is key to drug development. ‘[This] is a bottleneck in drug discovery and it is typically done through proteomic approaches, which tend to be very laborious, time consuming and do not guarantee success in regards to linking drug target binding to modulation of disease,’ explains Gonçalo Bernardes, a researcher at the University of Cambridge, UK, and one of the lead authors of the study. He explains that artificial intelligence ‘also provides research hypotheses that need to be experimentally confirmed, but in a much faster and economical way’."
The algorithm suggested targets for the natural product β-lapachone, including the enzyme 5-lipoxygenase, which was a perfect match.
"Researchers used two different machine learning methods: ‘One gives a bind/don’t bind answer … and the other uses several decision trees to predict an affinity value,’ explains Bernardes. Then, the algorithm gives a prediction."
"Bernardes and his team relied on a huge database of compounds and drug targets they used to ‘teach’ a single desktop computer."